Cargando…
Rationale and Design of a Randomized Controlled Clinical Trial on the Safety and Efficacy of Flecainide versus Amiodarone in the Cardioversion of Atrial Fibrillation at the Emergency Department in Patients with Coronary Artery Disease (FLECA-ED)
Pharmacologic cardioversion is a well-established alternative to electric cardioversion for hemodynamically stable patients, as it skips the risks associated with anesthesia. A recent network meta-analysis identifies the most effective antiarrhythmics for pharmacologic cardioversion with flecainide...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299428/ https://www.ncbi.nlm.nih.gov/pubmed/37373655 http://dx.doi.org/10.3390/jcm12123961 |
_version_ | 1785064361552773120 |
---|---|
author | Tsioufis, Panagiotis Tsiachris, Dimitris Doundoulakis, Ioannis Kordalis, Athanasios Antoniou, Christos-Konstantinos Vlachakis, Panayotis K. Theofilis, Panagiotis Manta, Eleni Gatzoulis, Konstantinos A. Parissis, John Tsioufis, Konstantinos |
author_facet | Tsioufis, Panagiotis Tsiachris, Dimitris Doundoulakis, Ioannis Kordalis, Athanasios Antoniou, Christos-Konstantinos Vlachakis, Panayotis K. Theofilis, Panagiotis Manta, Eleni Gatzoulis, Konstantinos A. Parissis, John Tsioufis, Konstantinos |
author_sort | Tsioufis, Panagiotis |
collection | PubMed |
description | Pharmacologic cardioversion is a well-established alternative to electric cardioversion for hemodynamically stable patients, as it skips the risks associated with anesthesia. A recent network meta-analysis identifies the most effective antiarrhythmics for pharmacologic cardioversion with flecainide exhibiting a more efficacious and safer profile towards faster cardioversion. Moreover, the meta-analysis of class Ic antiarrhythmics revealed an absence of adverse events when used for pharmacologic cardioversion of AF in the ED, including patients with structural heart disease. The primary goals of this clinical trial are to prove the superiority of flecainide over amiodarone in the successful cardioversion of paroxysmal atrial fibrillation in the Emergency Department and to prove that the safety of flecainide is non-inferior to amiodarone in patients with coronary artery disease without residual ischemia, and an ejection fraction over 35%. The secondary goals of this study are to prove the superiority of flecainide over amiodarone in the reduction in hospitalizations from the Emergency Department due to atrial fibrillation in the time taken to achieve cardioversion, and in the reduction in the need to conduct electrical cardioversion. |
format | Online Article Text |
id | pubmed-10299428 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102994282023-06-28 Rationale and Design of a Randomized Controlled Clinical Trial on the Safety and Efficacy of Flecainide versus Amiodarone in the Cardioversion of Atrial Fibrillation at the Emergency Department in Patients with Coronary Artery Disease (FLECA-ED) Tsioufis, Panagiotis Tsiachris, Dimitris Doundoulakis, Ioannis Kordalis, Athanasios Antoniou, Christos-Konstantinos Vlachakis, Panayotis K. Theofilis, Panagiotis Manta, Eleni Gatzoulis, Konstantinos A. Parissis, John Tsioufis, Konstantinos J Clin Med Study Protocol Pharmacologic cardioversion is a well-established alternative to electric cardioversion for hemodynamically stable patients, as it skips the risks associated with anesthesia. A recent network meta-analysis identifies the most effective antiarrhythmics for pharmacologic cardioversion with flecainide exhibiting a more efficacious and safer profile towards faster cardioversion. Moreover, the meta-analysis of class Ic antiarrhythmics revealed an absence of adverse events when used for pharmacologic cardioversion of AF in the ED, including patients with structural heart disease. The primary goals of this clinical trial are to prove the superiority of flecainide over amiodarone in the successful cardioversion of paroxysmal atrial fibrillation in the Emergency Department and to prove that the safety of flecainide is non-inferior to amiodarone in patients with coronary artery disease without residual ischemia, and an ejection fraction over 35%. The secondary goals of this study are to prove the superiority of flecainide over amiodarone in the reduction in hospitalizations from the Emergency Department due to atrial fibrillation in the time taken to achieve cardioversion, and in the reduction in the need to conduct electrical cardioversion. MDPI 2023-06-10 /pmc/articles/PMC10299428/ /pubmed/37373655 http://dx.doi.org/10.3390/jcm12123961 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Study Protocol Tsioufis, Panagiotis Tsiachris, Dimitris Doundoulakis, Ioannis Kordalis, Athanasios Antoniou, Christos-Konstantinos Vlachakis, Panayotis K. Theofilis, Panagiotis Manta, Eleni Gatzoulis, Konstantinos A. Parissis, John Tsioufis, Konstantinos Rationale and Design of a Randomized Controlled Clinical Trial on the Safety and Efficacy of Flecainide versus Amiodarone in the Cardioversion of Atrial Fibrillation at the Emergency Department in Patients with Coronary Artery Disease (FLECA-ED) |
title | Rationale and Design of a Randomized Controlled Clinical Trial on the Safety and Efficacy of Flecainide versus Amiodarone in the Cardioversion of Atrial Fibrillation at the Emergency Department in Patients with Coronary Artery Disease (FLECA-ED) |
title_full | Rationale and Design of a Randomized Controlled Clinical Trial on the Safety and Efficacy of Flecainide versus Amiodarone in the Cardioversion of Atrial Fibrillation at the Emergency Department in Patients with Coronary Artery Disease (FLECA-ED) |
title_fullStr | Rationale and Design of a Randomized Controlled Clinical Trial on the Safety and Efficacy of Flecainide versus Amiodarone in the Cardioversion of Atrial Fibrillation at the Emergency Department in Patients with Coronary Artery Disease (FLECA-ED) |
title_full_unstemmed | Rationale and Design of a Randomized Controlled Clinical Trial on the Safety and Efficacy of Flecainide versus Amiodarone in the Cardioversion of Atrial Fibrillation at the Emergency Department in Patients with Coronary Artery Disease (FLECA-ED) |
title_short | Rationale and Design of a Randomized Controlled Clinical Trial on the Safety and Efficacy of Flecainide versus Amiodarone in the Cardioversion of Atrial Fibrillation at the Emergency Department in Patients with Coronary Artery Disease (FLECA-ED) |
title_sort | rationale and design of a randomized controlled clinical trial on the safety and efficacy of flecainide versus amiodarone in the cardioversion of atrial fibrillation at the emergency department in patients with coronary artery disease (fleca-ed) |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299428/ https://www.ncbi.nlm.nih.gov/pubmed/37373655 http://dx.doi.org/10.3390/jcm12123961 |
work_keys_str_mv | AT tsioufispanagiotis rationaleanddesignofarandomizedcontrolledclinicaltrialonthesafetyandefficacyofflecainideversusamiodaroneinthecardioversionofatrialfibrillationattheemergencydepartmentinpatientswithcoronaryarterydiseaseflecaed AT tsiachrisdimitris rationaleanddesignofarandomizedcontrolledclinicaltrialonthesafetyandefficacyofflecainideversusamiodaroneinthecardioversionofatrialfibrillationattheemergencydepartmentinpatientswithcoronaryarterydiseaseflecaed AT doundoulakisioannis rationaleanddesignofarandomizedcontrolledclinicaltrialonthesafetyandefficacyofflecainideversusamiodaroneinthecardioversionofatrialfibrillationattheemergencydepartmentinpatientswithcoronaryarterydiseaseflecaed AT kordalisathanasios rationaleanddesignofarandomizedcontrolledclinicaltrialonthesafetyandefficacyofflecainideversusamiodaroneinthecardioversionofatrialfibrillationattheemergencydepartmentinpatientswithcoronaryarterydiseaseflecaed AT antoniouchristoskonstantinos rationaleanddesignofarandomizedcontrolledclinicaltrialonthesafetyandefficacyofflecainideversusamiodaroneinthecardioversionofatrialfibrillationattheemergencydepartmentinpatientswithcoronaryarterydiseaseflecaed AT vlachakispanayotisk rationaleanddesignofarandomizedcontrolledclinicaltrialonthesafetyandefficacyofflecainideversusamiodaroneinthecardioversionofatrialfibrillationattheemergencydepartmentinpatientswithcoronaryarterydiseaseflecaed AT theofilispanagiotis rationaleanddesignofarandomizedcontrolledclinicaltrialonthesafetyandefficacyofflecainideversusamiodaroneinthecardioversionofatrialfibrillationattheemergencydepartmentinpatientswithcoronaryarterydiseaseflecaed AT mantaeleni rationaleanddesignofarandomizedcontrolledclinicaltrialonthesafetyandefficacyofflecainideversusamiodaroneinthecardioversionofatrialfibrillationattheemergencydepartmentinpatientswithcoronaryarterydiseaseflecaed AT gatzouliskonstantinosa rationaleanddesignofarandomizedcontrolledclinicaltrialonthesafetyandefficacyofflecainideversusamiodaroneinthecardioversionofatrialfibrillationattheemergencydepartmentinpatientswithcoronaryarterydiseaseflecaed AT parissisjohn rationaleanddesignofarandomizedcontrolledclinicaltrialonthesafetyandefficacyofflecainideversusamiodaroneinthecardioversionofatrialfibrillationattheemergencydepartmentinpatientswithcoronaryarterydiseaseflecaed AT tsioufiskonstantinos rationaleanddesignofarandomizedcontrolledclinicaltrialonthesafetyandefficacyofflecainideversusamiodaroneinthecardioversionofatrialfibrillationattheemergencydepartmentinpatientswithcoronaryarterydiseaseflecaed |